Post-Vaccine Distribution, Mergers Will Dominate Biotech Industry ETFs

The COVID-19 pandemic put biotech in the spotlight as companies around the globe worked feverishly to create a vaccine. Once a tried-and-true vaccine is developed and subsequently incorporated as standard fare in medical practice, one driver of biotech will be mergers and acquisitions, which should...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.